1. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection;Cooper;N. Engl. J. Med.,2008
2. Raltegravir with optimized background therapy for resistant HIV-1 infection;Steigbigel;N. Engl. J. Med.,2008
3. Zolopa , A. Mullen , M. Berger , D. Ruane , P. Hawkins , T. Zhong , L. Chuck , S. Enejosa , J. Kearney , B. Cheng , A. The HIV integrase inhibitor GS-9137 demonstrates potent ARV activity in treatment-experienced patients 2007 119
4. Resistance to the HIV-integrase inhibitor raltegravir: Analysis of protocol 005, a phase 2 study in patients with triple-class resistant HIV-1 infection;Hazuda;Antivir. Ther.,2007
5. Resistance and cross-resistance to first generation integrase inhbitors: Insights from a phase II study of elvitegravir (GS-9137);McColl;Antivir. Ther.,2007